The last full week of October was action-packed for Biogen Inc., with updated Phase II data for the Alzheimer's drug BAN2401 and progress for a number of other neuroscience assets in the pipeline, but also two mid-stage failures – vixotrigine in sciatica and dapirolizumab pegol in lupus.
The pipeline update comes at a time of concern about coming competition for the company's rare disease drug Spinraza and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?